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Abstract
Studies have addressed cost-effectiveness of syphilis testing of pregnant women in high-
prevalence settings. This study compares costs of rapid syphilis testing (RST) with labora-
tory-based rapid plasma reagin (RPR) tests in low-prevalence settings in Peru. The RST
was introduced in a tertiary-level maternity hospital and in the Ventanilla Network of primary
health centers, where syphilis prevalence is approximately 1%. The costs per woman tested
and treated with RST at the hospital were $2.70 and $369 respectively compared with
$3.60 and $740 for RPR. For the Ventanilla Network the costs per woman tested and
treated with RST were $3.19 and $295 respectively compared with $5.55 and $1454 for
RPR. The cost per DALY averted using RST was $46 vs. $109 for RPR. RST showed lower
costs compared to the WHO standard costs per DALY ($64). Findings suggest syphilis
screening with RST is cost-effective in low-prevalence settings.
Introduction
Syphilis remains an important global health issue. TheWorld Health Organization (WHO) esti-
mates that every year 1.5 million pregnant women are infected with syphilis [1]. At least half of
untreated infected pregnant women will have serious adverse events associated with syphilis,
including stillbirths, neonatal or early infant deaths, and infants with clinical signs of the disease
[1]. Penicillin is the treatment of choice and can prevent complications and congenital syphilis
if pregnant women are treated early in pregnancy, ideally before 20 weeks of gestation [2].
Although almost every country in the world has policies or guidelines related to syphilis screen-
ing in antenatal care (ANC) implementation is still a problem in many settings; women are often
not screened, results are not always available and infected women fail to undergo treatment[3].
Rapid syphilis tests (RSTs) are now available for use at the point of care. Since results are
available in 15–20 minutes, they allow for same-day testing and treatment. Most currently
available RSTs are treponemal tests, which detect antibodies to treponemal antigens and have
high sensitivity and specificity when compared to non-treponemal screening tests such as the
rapid plasma regain (RPR) test in low prevalence populations such as pregnant women. RSTs
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therefore present an opportunity for improving screening programs in ANC, especially in
resource limited settings [4–5].
Although there is some published literature on costs and cost-effectiveness of rapid syphilis
testing, almost all of it relates to African countries. Limited information exists on settings with
relatively low maternal syphilis prevalence, such as most Latin American countries. Further-
more, work on the subject tends to be centred on models that rely heavily on assumptions (e.g
sensitivities and specificities, coverage of screening and treatment, etc) rather than on primary
data [6–16].
As part of a six-country implementation study [17], rapid syphilis tests SD BIOLINE Syphi-
lis 3.01 (Standard Diagnostics, Korea) were introduced in Peru in 2010, through the CISNE
Project and, soon after, their use became national policy [18]. The objective of this paper is to
compare the cost-effectiveness analysis of a point-of-care test with the standard of care (rapid
plasma reagin (RPR) test) for reproductive care services in Peru, a setting with low prevalence
of maternal syphilis, and to compare their cost-effectiveness in three services: antenatal care
(ANC), delivery and miscarriage services.
Methods
RST was introduced in two low prevalence (1%) settings in Peru: (1) a tertiary-level referral
maternity hospital with the largest number of deliveries in the country, the Instituto Nacional
Materno Perinatal (INMP); and (2) the Ventanilla Network, consisting of 16 health facilities
(which include 15 health centers and one small hospital), where RST was implemented
together with rapid HIV testing: “two tests one stick, or two for one”[18]. The Peruvian
National Guidelines recommended syphilis screening with RPR for all pregnant women at the
first ANC visit and also for pregnant women seen at miscarriage services and delivery/emer-
gency services, mainly to detect congenital syphilis cases and treat them appropriately (with
Benzathine penicillin 1.2 million units IM every week for three weeks) and to prevent future
new cases of congenital syphilis. For the cost-effectiveness analysis we included INMP and five
of the health facilities of the Ventanilla Network. We classified all the health facilities within
the Ventanilla Network into four types: (1) type I, small hospital with laboratory; (2) type II,
health center with laboratory; (3) type III, health center without a laboratory (blood is drawn at
the facility, sent daily to type II facilities where samples are processed and returned to type III
facility), and (4) type IV, health center without a laboratory (patients are referred to type II
facility to have blood drawn, they have to return to the type II facility at a later date to pick up
results, and then go back to the type IV facility to see their provider).
For the study we randomly chose one facility each from type I (the only one of this type),
type III, and type IV, and two facilities from type II. All the costing data were obtained in early
2010. Patient flows for RST and RPR were mapped. Cost data were collected for both RPR and
RST based on the Guidelines for Cost Effectiveness Analysis of Syphilis Screening Strategies
[19].
Cost Analysis
Costs considered for RPR included: laboratory supplies, space rental, allocated staff salaries
and treatment costs. These costs were associated with blood sampling, processing of the blood
sample and reading of the RPR, and with treatment of a positive index case and of one partner.
Costs considered for RST included: expenses for the implementation activities (advocacy meet-
ings with authorities, training, supervision, and monitoring) and the cost of implementing the
QA system. Costs of supplies, such as lancets, alcohol swabs, kits (cassette and buffer), gloves,
biosecurity devices, supplies for treatment of the positive index case and partner (assuming all
Rapid Syphilis Testing and Cost-Effectiveness
PLOS ONE | DOI:10.1371/journal.pone.0149568 March 7, 2016 2 / 11
partners receive treatment), among others, as well as allocated staff salaries, were also included.
For the Ventanilla Network facilities, costs of personnel time and building space were allocated
equally between HIV and syphilis screening, as RST was rolled out alongside rapid HIV testing.
The information on unit price of materials and supplies, and costs associated with person-
nel, laboratory equipment, electricity and water consumption of the respective health facilities,
were provided by offices of the Callao Regional Health Directorate for the Ventanilla Network.
For INMP, data were obtained through the logistics office of the hospital. Each of the offices
was visited, staff responsible for purchasing supplies were interviewed and information from
invoices and reports was collected. Data on training costs associated with RST were collected
through bills, invoices of supplies and reagents purchased by the CISNE Project provided by
the project manager. Data on associated costs of training were obtained by allocating salaries of
project staff involved in the activities.
Project Outputs and Unit Costs
Project outputs included: number of pregnant women tested in each of the facilities, number of
women with reactive tests for syphilis and number of women treated. The data for RST was
obtained from records of the CISNE Project implementation, which took place from January
to November 2010 (data was projected for the whole year). Data for RPR were obtained from
2009 statistical reports from each health facility. The economic unit cost per woman tested and
the cost per woman treated were both calculated for each service within each facility. Based on
the model presented by Terris-Prestholt et al [20] true cases treated were estimated. This
model used quality assurance data from Ventanilla to assess the performance of the RPR and
RST tests in this setting. Based on this model, the percentage of true cases treated among
women who were tested and treated is 90.7% with RST and 33% with RPR. These figures were
obtained by comparing field performances against laboratory-based RPR and Treponema Pal-
lidum Hemagglutination Assay tests (TPHA). Disability-adjusted life years (DALY) averted
were only calculated for adverse outcomes in infants, and estimated by the number of women
seen in ANC, prevalences, diagnostic performance and treatment rates. Using standard DALY
inputs (3% discount rate and stillbirth considered a full life lost), each true case treated is
assumed to avert 5.73 DALYs in Peru. The estimation of DALYs for this study followed the
methods presented by Terris-Prestholt et al [20].
Sensitivity Analysis
A univariate sensitivity analysis was performed to determine the impact of uncertainty of costs
and output. Factors included were: discount rate (variation from 3% to 9%); working hours of
the health workers (variation from 6 to 8 hours per day); screening rates for syphilis (variation
from 57% to 100%); exchange rate (US dollars (USD) to Peruvian new soles (PNS) with a varia-
tion of 2.638 to 2.910 PNS:USD); syphilis prevalence (variation from 0.6% to 2.2%); building
costs (increments of 22.1%); and health personnel salaries (both for screening and for treat-
ment, variation between 0% to 50%).
The Ethics Committee at Universidad Peruana Cayetano Heredia reviewed and approved
the main study (Approval number 55202). The current study did not involve participation of
human beings. We have verified and confirmed that we have no identifying information for
patients.
Results
For 2010 (January to December) we projected a total of 17,919 and 3,908 women screened with the
RST at INMP and at the five health facilities from the Ventanilla Network, respectively. Women
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were seen at ANC services, miscarriage services, and delivery and emergency services. Screening
coverage for RST was 95% at INMP and 90% at the five facilities of the Ventanilla Network. For
RPR estimated coverage was lower: 62% at INMP and 34% for the Ventanilla Network. Syphilis
prevalence with RST was 0.9% at INMP and 1.2% at the Ventanilla Network health facilities. The
prevalences observed with RPR were lower: 0.6% at INMP and 0.5% at the Ventanilla Network.
Regarding treatment, 91% and 90% of RST-positive women from INMP and from the Ven-
tanilla Network were treated, respectively. Eighty-three percent of RPR-positive women
received appropriate treatment at both INMP and the Ventanilla Network (Table 1).
Costs
Total economic costs associated with screening with RST and subsequent treatment ranged
from $1,008 to $46,067 per facility. Supplies accounted for the greatest share of total costs
(53.4%), followed by the personnel costs (23.6%) and start-up costs (14.8%). Quality assurance
costs represented only 2.5% of costs. For RPR the total economic costs of screening and treat-
ment ranged from $403 to $39,957. Supplies costs accounted for 35% of total costs, followed by
personnel costs (31.3%) and store and building costs (27.7%) (Table 2) (Fig 1).
Unit Costs
The cost per woman tested at INMP was estimated to be $2.70 for RST and $3.60 for RPR. The
cost per woman treated was $369 for RST and $740 for RPR.
At the Ventanilla Network, the cost per woman tested (average of the five establishments)
was $3.19 for RST and $5.55 for RPR. The cost per woman treated was $295 for RST and
Table 1. Screening and treatment outputs.
RST Outputs (2010) INMP Facility A* Facility B Facility C Facility D Facility E All ﬁve facilities
Total of women in ANC/MS/DE** 17919 2509 649 268 214 268 3908
Women Tested 17084 2287 547 232 206 241 3513
Women Positive 150 26 8 5 1 3 43
Women who required treatment*** 137 26 7 5 1 3 42
Women Treated 125 23 7 4 1 3 38
% of women tested 95% 91% 84% 87% 96% 90% 90%
% Reactive 0.9% 1.1% 1.5% 2.2% 0.5% 1.2% 1.2%
% of positives treated 91% 88% 100% 80% 100% 100% 90%
Real cases treated in women**** 113 21 6 4 1 3 35
RPR Outputs (2010)
Total of women in ANC/MS/DE** 17919 2509 649 268 214 268 3908
Women Tested 11113 591 296 147 123 154 1311
Women Positive 65 3.8 0.8 0.4 0.4 0.5 6
Women Treated 54 2.9 0.7 0.4 0.3 0.4 5
% of women tested 62% 24% 46% 55% 57% 57% 34%
% Reactive 0.6% 0.6% 0.3% 0.3% 0.3% 0.3% 0.5%
% of positives treated 83% 76% 88% 100% 75% 80% 83%
Real cases treated in women**** 18 1.0 0.2 0.1 0.1 0.1 1.5
* Establishments A is type I, B and C are type II, D is type III and E type IV. Facilities A through E are located at Ventanilla Network
**ANC: antenatal care services. MS: miscarriage services. DE: Delivery and emergency services.
*** Some women had a clear history of previous treatment (recent) and it was deemed they did not need treatment.
**** Calculated using model from Terris-Prestholt et al. (20)
doi:10.1371/journal.pone.0149568.t001
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$1,454 for RPR. Costs per woman tested and treated by type of service (ANC, miscarriage ser-
vices and delivery/emergency) for INMP and for the Ventanilla Network for both RST and
RPR are compared in Fig 2.
Table 2. Total screening and treatment costs of RST and RPR (USD).
RST costs ($USD) INMP Facility A* Facility B Facility C Facility D Facility E All ﬁve facilities
Start-up and training costs $4,369 $1,580 $894 $610 $465 $539 $4,088
Testing and treatment costs $41,261 $3,662 $969 $538 $473 $496 $6,138
Capital $2,493 $238 $74 $95 $95 $60 $562
Personnel $12,323 $597 $212 $146 $125 $137 $1,217
Supplies $26,257 $2,815 $679 $294 $250 $296 $4,334
Waste management $188 $12 $4 $3 $3 $3 $25
Quality Assurance costs $437 $486 $190 $158 $70 $80 $984
TOTAL COSTS RST $46,067 $5,728 $2,053 $1,306 $1,008 $1,115 $11,210
Unit Costs
Cost per woman tested RST** $2.70 $2.50 $3.75 $5.63 $4.89 $4.63 $3.19
Cost per woman treated RST** $369 $249 $293 $327 $1008 $372 $295
Cost per true case treated *** $308 $295 $390 $725 $508 $478 $366
RST costs ($USD) INMP Facility A* Facility B Facility C Facility D Facility E All ﬁve facilities
Start-up and training costs
Testing and treatment costs $39957 $3643 $1522 $1067 $636 $403 $7271
Capital $11335 $1775 $645 $614 $162 $47 $3243
Personnel $12243 $1199 $518 $295 $336 $185 $2533
Supplies $15271 $593 $293 $125 $101 $153 $1265
Transportation $18 $18
Waste management $1108 $76 $66 $33 $19 $18 $212
Quality Assurance costs
TOTAL COSTS RPR $39957 $3643 $1522 $1067 $636 $403 $7271
Unit Costs
Cost per woman tested RPR $3.60 $6.16 $5.14 $7.26 $5.17 $2.62 $5.55
Cost per woman treated RPR $740 $1,256 $2,174 $2,668 $2,120 $1,008 $1,454
Cost per true case treated*** $621 $1142 $831 $1038 $997 $473 $946
*Facilities A through E are located at Ventanilla Network
**Includes start-up and training costs
***Calculated using model from Terris-Prestholt et al. (20)
doi:10.1371/journal.pone.0149568.t002
Fig 1. RST and RPR cost components.
doi:10.1371/journal.pone.0149568.g001
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Fig 2. Costs per woman screened and treated, by service comparing RST vs RPR at INMP and Ventanilla Network.
doi:10.1371/journal.pone.0149568.g002
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The cost per DALY averted by screening in ANC was $46 for RST and $109 for RPR. These
number do not change much when reducing the proportion of stillbirths from 4.6% to 0% ($42
and $100 for RST and RPR respectively). Although either intervention could judged as very
cost-effective compared with the Peruvian GDP per capita for 2011 of $5759 USD, screening
with RST was more cost-effective than with RPR at all health facilities.
Cost per woman tested was used in the univariate sensitivity analysis. For RST, the cost per
woman screened increased when the number of positive cases increased and when salaries
increased. However, when the coverage of screening increased the cost per woman tested
decreased. For RPR costs decreased when the number of hours worked and the screening cov-
erage increased. But if the salaries or the prevalence of syphilis increased, the cost per women
tested also increased (Table 3, Fig 3). Cost-effectiveness of RST is thus sensitive to the coverage
Table 3. Univariate sensitivity analysis.
Parameters varied Cost per woman tested
(USD)
Parameters varied Cost per woman tested
(USD)
RST RPR RST RPR
Discount Rate Prevalence
3% 2.78 3.78 0.6% 2.73 3.80
6% 2.78 3.79 0.9% 2.78 3.85
9% 2.78 3.80 2.2% 2.95 4.03
Working Hours Building Costs
6 hours 2.78 3.80 100.0% 2.78 3.80
7 hours 2.68 3.63 104.4% 2.79 3.84
8 hours 2.60 3.50 122.1% 2.81 3.99
Acceptance rates Salaries
57% 3.22 3.80 100% 2.78 3.80
94% 2.78 3.46 120% 2.96 4.04
100% 2.75 3.42 150% 3.22 4.40
Exchange rates
1USD = 2.800 soles 2.78 3.80
1USD = 2.910 soles 2.68 3.66
1USD = 2.638 soles 2.95 4.03
doi:10.1371/journal.pone.0149568.t003
Fig 3. Univariate sensitivity analysis.
doi:10.1371/journal.pone.0149568.g003
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of screening, disease prevalence and salaries, while RPR is also sensitive to the number of work-
ing hours.
Discussion
Peruvian reproductive health guidelines recommend syphilis screening for all women in ANC
and for women attending reproductive health services: miscarriage services and delivery-emer-
gency services. After the successful implementation of the rapid syphilis test in Peru [18], the
guidelines promote using them to improve coverage of screening and treatment. Syphilis prev-
alence was found to be lower when using the RPR test (0.6% and 0.5% at the INMP and Venta-
nilla Network, respectively) compared to when the RST was used (0.9% and 1.2%,
respectively). This difference was found in part to be related to the poor performance of the
RPR. A QA evaluation of the RPR performance showed that half of the positive syphilis tests
were missed by the RPR performed at the facilities due to several factors: lack of equipment
(centrifuges and/or rotators), staff not following procedures adequately, and the poor quality of
reagent and cards. Another reason to explain why RST detected more cases than RPR is that
RST detects women with syphilis regardless of whether they have current infection or past
treated infection. Prevalence of past syphilis infections is expected to be low, as women in ANC
are relatively young and from a low risk population, thus they would not contribute much to
overtreatment. Nevertheless, the benefit of improving treatment coverage among infected
women outweighs the potential risk and costs of unnecessary treatment for some uninfected
women. Since we have no good serological test to detect re-infection and the serious conse-
quence of missing any reinfections, all women with a RST positive result should be treated. The
screening and treatment coverage was also higher when using RST.
The economic comparisons did not include implementation, training or QA activities for
RPR, since those activities had taken place long ago or were not done on a regular basis. Those
costs were only included for RST in order to get a more accurate view of the start-up costs
involved in introduction. Start-up costs for RST represented almost 15% of the economic costs
but, compared with RPR, personnel costs were much lower in proportion (23.6% for RST vs
31.3% for RPR). Supplies made up the greatest share of RST costs (53.4%). It is important to
highlight that the cost of RST for the country was significantly reduced by the introduction of a
national-level procedure to purchase centrally (as one large national bulk purchase of RSTs)
and using UNICEF’s procurement system, which led to much lower costs than purchasing
them through national commercial distributors. Peru has adopted this system and Peruvian
public health professionals are attempting to share lessons learned with other Latin American
countries.
Cost per woman tested, cost per woman treated and cost per DALY averted with RST were
lower compared with the costs related to RPR ($3.19, $295, and $46 for RST, and $5.55, $1454,
and $109 for RPR, respectively). This suggests that even for a setting with low syphilis preva-
lence the RST is more cost-effective than the RPR.
Previous studies, mainly focusing on African countries and largely based on cost-modeling,
have reported that cost per woman screened and/or cost per woman treated varied according
to the costs included in the analysis or the prevalence of the disease [6,9–14]. For example, a
study in Bolivia, which did not include implementation or QA costs, found that the average
cost per woman tested was $1.48 and $1.91 using the RPR and a rapid strip test, respectively
[7]. A study from Tanzania [15] showed an average cost per woman screened of $1.92 for RST
and $2.32 for the RPR. The costs per woman treated were $21.35 for RST and $12.96 for the
RPR. A total of 6362 women were tested with RST and only 224 with RPR, with reactivity rates
ranging from 9% to 59%, depending of the clinic/site. The study concluded that RST was less
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expensive than RPR in the Tanzania setting. In most of the previous studies the costs per
woman screened with RST was higher in comparison with the RPR, although the use of RST
was deemed more cost-effective than that of the RPR because a higher proportion of women
testing positive were treated when using a point of care test. Only the Tanzanian study found
that the screening costs, in this high prevalence setting, were lower with RST than with RPR.
Our study produced similar findings but in a low- prevalence setting (around 1%). These find-
ings may resonate with other Latin American countries, most of which have similarly low prev-
alence rates.
A recent article modeled the cost, health impact, and cost-effectiveness of expanded syphilis
screening and treatment in ANC for eight generic country case scenarios. Using syphilis preva-
lence as one of the factors, the study concluded that countries with high prevalence, low current
service coverage, and high healthcare costs would benefit most from expanded screening and
services. However, they also acknowledge the need of local epidemiologic and programmatic
data to adjust the models [10]. The findings from our study show that there could even be
important benefits in low-prevalence settings if screening coverage is improved by using RST.
The implementation of a QA system for screening with RST in our study represented a very
small percent (2.5%) of the total economic costs. The QA costs included training on QA issues,
preparation of the dried tube specimens [19], delivery of the packages to the clinics and the vis-
its for external and internal QA and evaluations. On average the cost of the QA system per
woman screened was $ 0.40 with a range from $ 0.03 to $ 0.68 (lower at the larger health estab-
lishments reflecting economies of scale). These costs were lower than those presented in the
Tanzania study [15]. This could be explained by the differences in distances between remote
establishments in Tanzania as opposed to the Ventanilla Network in Peru, and the frequency
of the evaluations. Evaluations were reported monthly in Tanzania. In Peru, visits and moni-
toring were included in the implementation phase (which are reflected in start-up costs, not in
the QA costs), the first external QA (evaluation of the performance of the health professionals
reading the RST) was performed at the end of the training, and then repeated every six months.
The internal evaluation (to assess the quality of the kits) was also performed every six months.
It is clear that the costs and effects of a QA system will vary according to the intensity of the
program. One important issue is to find the right balance between the need for QA, the budget
available, the prevalence of the disease (the lower the prevalence, the higher the need of QA),
staff turnover and the potential increased workload for the health system staff. QA external
evaluations were carried out every six months as the initial QA showed very good performance,
due to staff turnover occurring around every six months and to budget constraints. Although
there were some initial problems attributed to presbyopia (farsightedness), these were resolved
by recommending reading glasses to the health workers carrying out the tests. Further studies
are needed to evaluate the ideal frequency of QA visits, which will need to be tailored to differ-
ent settings.
There are some limitations to this study. Data on prevalence, screening, and treatment in
relation to RPR were collected from different statistical reports at each health facility, which
showed some inconsistencies. On the other hand RST data were collected prospectively. Cost-
ing data varied greatly by health center. Although different types of health centers were
included, costs at other health facilities may vary and we cannot be sure how much. For the
cost-effectiveness analysis we lumped together data from ANC, miscarriage and delivery/emer-
gency services. We did not analyze how cost effective it is to screen these different populations,
which are included in the National Peruvian Guidelines. That analysis was beyond the scope of
this paper, since it will need the development of a model that incorporates other reproductive
issues, however this is an interesting area of future work.
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This study also has important strengths. It includes costs of implementation and QA, which
are essential for countries interested in introducing RST. It also offers data for countries with
low prevalences of syphilis, like most Latin American countries, showing that the implementa-
tion of RST is cost-effective, a crucial finding given that the region has taken on the challenge
of eliminating congenital syphilis [21]. This study shows that RSTs could potentially be a key
element in achieving this goal.
Conclusions
Even in low prevalence settings (1% prevalence of maternal syphilis), syphilis screening using
rapid syphilis testing is cost-effective and cheaper than RPR. Costs may vary depending on the
size of the health facility, mainly due to economies of scale. The cost associated with imple-
menting a QA system represented a small percent of the economic costs but this is critical for a
well-functioning program.
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